Home > Publications database > Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo. > print

001     309984
005     20260220155857.0
024 7 _ |a 10.1158/2767-9764.CRC-25-0599
|2 doi
024 7 _ |a pmid:41566838
|2 pmid
037 _ _ |a DKFZ-2026-00410
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Traichel, Jasmin
|0 P:(DE-He78)72f465234033973e5e61125cf51b50b0
|b 0
|u dkfz
245 _ _ |a Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo.
260 _ _ |a Philadelphia, Pa.
|c 2026
|b American Association for Cancer Research
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771599522_3240618
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity of BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Proto-Oncogene Proteins B-raf
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a BRAF protein, human
|0 EC 2.7.11.1
|2 NLM Chemicals
650 _ 7 |a Protein Kinase Inhibitors
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: genetics
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: pathology
|2 MeSH
650 _ 2 |a Colorectal Neoplasms: drug therapy
|2 MeSH
650 _ 2 |a Proto-Oncogene Proteins B-raf: genetics
|2 MeSH
650 _ 2 |a Proto-Oncogene Proteins B-raf: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cell Line, Tumor
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a Protein Kinase Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Drug Resistance, Neoplasm
|2 MeSH
700 1 _ |a Metzger, Ariane
|0 0009-0008-8611-3415
|b 1
700 1 _ |a Walz, Maria
|0 0009-0009-8381-415X
|b 2
700 1 _ |a Feuerstein, Reinhild
|0 0000-0002-4437-2194
|b 3
700 1 _ |a Wohlfeil, Nadine
|0 0000-0003-3228-053X
|b 4
700 1 _ |a Metzger, Patrick
|b 5
700 1 _ |a Marx, Lisa
|0 0000-0001-5745-2161
|b 6
700 1 _ |a Asdih, Célia
|0 0000-0002-7639-9332
|b 7
700 1 _ |a Lindenthal, Agnes
|0 0009-0009-0584-7108
|b 8
700 1 _ |a Seger, Alina
|0 0009-0008-1541-1482
|b 9
700 1 _ |a Schrimpf, Jule
|0 0009-0007-9776-817X
|b 10
700 1 _ |a Nardella, Luigi L
|b 11
700 1 _ |a Kowar, Silke
|b 12
700 1 _ |a Frew, Ian J
|0 0000-0003-2735-5509
|b 13
700 1 _ |a Halbach, Sebastian
|0 0000-0002-6827-8178
|b 14
700 1 _ |a Kesselring, Rebecca
|0 0000-0001-8131-7605
|b 15
700 1 _ |a Boerries, Melanie
|0 0000-0002-3670-0602
|b 16
700 1 _ |a Griffin, Ricarda
|0 0000-0003-1368-2832
|b 17
700 1 _ |a Brummer, Tilman
|0 P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9
|b 18
|u dkfz
773 _ _ |a 10.1158/2767-9764.CRC-25-0599
|g Vol. 6, no. 2, p. 320 - 339
|0 PERI:(DE-600)3098144-X
|n 2
|p 320 - 339
|t Cancer research communications
|v 6
|y 2026
|x 2767-9764
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)72f465234033973e5e61125cf51b50b0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 0000-0003-2735-5509
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 0000-0002-6827-8178
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 0000-0001-8131-7605
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 0000-0002-3670-0602
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)492a2f9f2a95bcb0609e37d1ce1e13a9
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-12-06T11:12:23Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-12-06T11:12:23Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2022-12-06T11:12:23Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2022-12-06T11:12:23Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK Koordinierungsstelle Freiburg
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21